April 27, 2023

Wieslab's Newsletter and Scientific Highlights – Spring 2023

Wieslab's Spring 2023 Newsletter presents the latest addition to our Neurology portfolio - a new panel for supporting the diagnosis of Autoimmune nodopathies - disorders separated from CIDP - according to the European Academy.

The letter also includes information about updates to our Autoimmune portfolio, relevant Scientific Highlights related to tests, and updates to our Diagnostic Test Portfolio.

Get the latest news from Wieslab Diagnostic Services. Find out about our tests and learn about new and exciting research within the fields of neurology and autoimmunity. 

Download Newsletter as .pdf


Click here to sign up for future Newsletters and get them delivered electronically.

April 27, 2023

Wieslab's Newsletter and Scientific Highlights – Spring 2023

Wieslab's Spring 2023 Newsletter presents the latest addition to our Neurology portfolio - a new panel for supporting the diagnosis of Autoimmune nodopathies - disorders separated from CIDP - according to the European Academy.

The letter also includes information about updates to our Autoimmune portfolio, relevant Scientific Highlights related to tests, and updates to our Diagnostic Test Portfolio.

Get the latest news from Wieslab Diagnostic Services. Find out about our tests and learn about new and exciting research within the fields of neurology and autoimmunity. 

Download Newsletter as .pdf


Click here to sign up for future Newsletters and get them delivered electronically.

NEUROLOGY

New Panel

Autoimmune nodopathies 
- disorders separated from CIDP 

Wieslab Diagnostic Services offers diagnostic testing for antibodies associated with autoimmune nodopathies.

Autoimmune nodopathies have until recently been regarded as subgroups of Chronic inflammatory demyelinating polyneuropathy (CIDP) but are now regarded as separate disorders according to the European Academy of Neurology. The antibodies described in autoimmune nodopathies include specificities against both nodal and paranodal antigens1-3

Our new panel supports subtyping CIDP-like conditions. The new panel includes testing of autoantibodies against:

  • NF155
  • NF186
  • CNTN1
  • CASPR1

View panel 620 - CIDP/Autoimmune Nodopathy

> Download Neurology Request Form

1. Appeltshauser, L. et al. Anti-pan-neurofascin antibodies induce subclass-related complement activation and nodo-paranodal damage. Brain awac418 (2022) doi:10.1093/brain/awac418.
2. Cortese, A. et al. Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype. Neurol Neuroimmunol Neuroinflamm 7, e639 (2020).
3. Querol, L. A. et al. The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies. Neurotherapeutics 19, 864–873 (2022).

 

Info: Single Tests       

Phosphorylated tau in threonine 181 (pTau-181)
– a blood-based biomarker (BBBM) 

Ultrasensitive detection of p-Tau181 in EDTA-plasma is a useful biomarker for diagnosing Alzheimer's Disease (AD) in its early stages.  pTau-181 biomarker strongly corresponds to the density of amyloid-β plaques and tau tangles detected by PET scanning 1,2. Elevated levels in plasma of pTau-181 reflect pathological changes in AD2–5.

LinkedIn Wieslab Diagnostics 1200x628px (13)

View test 987 - pTau-181  

1. Janelidze, S. et al. Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat Med 26, 379–386 (2020).
2. Karikari, T. K. et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. The Lancet Neurology 19, 422–433 (2020).
3. Suárez-Calvet, M. et al. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected. EMBO Mol Med 12, e12921 (2020).
4. Palmqvist, S. et al. Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med 27, 1034–1042 (2021).
5. Mattsson-Carlgren, N. et al. Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease. Sci Adv 6, eaaz2387 (2020).

 

AUTOIMMUNE

PORTFOLIO UPDATES

The following tests will be removed from our portfolio:  

  • ANCA-Panel (BPI, Azu, Cath. G, Elastase, Lactoferrin, Lysozyme), item 040, available until March 31, 2023
  • Capture MPO-ANCA, item 016, available until June 30, 2023
  • Capture PR3-ANCA, item 012, available until June 30,  2023
  • Urgent screening: anti-GBM, CapPR3-ANCA, and CapMPO-ANCA (Screening for RPGN and Pulmonary-renal syndrome), item 009, available until May 7, 2023

> Download the Autoimmune Request Form

Info: Single Tests     

Glomerular Basement Membrane (GBM) antibodies of subclass IgG4

The test can still be ordered as a routine or urgent test with results within 48h (during office hours).

GBM antibodies are diagnostic markers for anti-GBM disease (Goodpasture syndrome). Anti-GBM antibodies comprise all IgG subclasses, but usually, IgG1 predominates.

The isolated presence of anti-GBM of the IgG4 subclass has been reported in cases with severe lung disease (with or without mild kidney damage)1-3.

View test 100 - GBM Ig4

1. Boomsma, M. M. et al. Prediction of relapses in Wegener’s granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: A prospective study. Arthritis & Rheumatism 43, 2025–2033 (2000).
2. Segelmark, M. & Wieslander, J. IgG subclasses of antineutrophil cytoplasm autoantibodies (ANCA). Nephrology Dialysis Transplantation 8, 696–702 (1993).
3. Segelmark, M., Butkowski, R. & Wieslander, J. Antigen Restriction and IgG Subclasses Among Anti-GBM Autoantibodies. Nephrology Dialysis Transplantation 5, 991–996 (1990).

 

THERAPEUTIC DRUG MONITORING (TDM)

Optimize treatment by adjusting therapy based on TDM

Monitoring levels of biological drugs allows for optimizing treatment efficacy by adjusting therapy based on the patient's therapeutic response.

 

 

We offer determination of drug level, Anti-drug antibodies (ADA), and/or Neutralizing antibodies (Nabs).

Therapuetic Drug Monitoring

Scientific Highlights

This report by the Encephalitis Society highlights the global incidence, morbidity, and mortality of encephalitis, as well as the surveillance systems, diagnostics, treatments, and support available worldwide. The report suggests that the number of people affected by encephalitis each year is likely between 500,000 and 2,000,000, which is more than current estimates.

Furthermore, there are barriers to implementing diagnostics tests and treatments due to a lack of test availability and limited awareness among clinicians. This report aims to initiate a dialogue with key stakeholders who can influence many of the identified areas.

_Awareness Days 2023 (9)

 

The Complement system plays an important role in immune defenses and tissue remodeling. In addition, it has an important pathophysiological role in several autoimmune neurological diseases. Complement mediates the actions of pathogenic autoantibodies in Myasthenia Gravis and Neuromyelitis Optica spectrum disorders,  as well as diseases in the peripheral nervous system such as variants of Guillain–Barré syndrome, Autoimmune nodopathies (formerly described as a subtype of CIDP), disorders of the neuromuscular junction, Lambert-Eaton myasthenic syndrome, Dermatomyositis, and Necrotizing autoimmune myositis. Activation by the Complement system has also been reported in other neurodegenerative diseases affecting the central nervous system, such as Alzheimer’s, Amyotrophic lateral sclerosis, Autoimmune Encephalitis, and Multiple Sclerosis.

_Awareness Days 2022 (4)

 

The Kidney Disease Improving Global Outcomes (KDIGO) 2021 includes an updated Clinical Practice Guideline for the Management of Glomerular Diseases.  This guideline is the first to address the subtype of complement-mediated diseases. Key takeaways include that while kidney biopsy is considered the gold standard for diagnosis, kidney biopsy is not required to diagnose membranous nephropathy (MN) in a patient with nephrotic syndrome and a positive PLA2R antibody test. THSD7Aab test may be applied as an auxiliary non-invasive diagnostic method for PLA2R-negative MN. Patients with MN should be evaluated for associated conditions, regardless of whether anti-PLA2R antibodies and anti-THSD7A antibodies are present or absent. 

 

Download Scientific Highlights as .pdf

 

 

Untitled design (4)

 

DOWNLOAD the Wieslab Diagnostic Services App

YOUR EXPERT COMPANION FROM SAMPLE PREPARATION TO ANALYSIS RESULTS

In the app, you will be able to access information about the test portfolio and find practical information about pre-analytical sample handling and shipping.

We continuously will improve and expand the App, we are happy for your feedback about the function and its content.

Download App

LinkedIn Wieslab Diagnostics 1200x628px (1)

SEARCHING FOR A SPECIFIC MARKER OR A RESEARCH PARTNER?

Is the test you are looking for not on our Request Forms? Or are you looking for a partner for testing within a clinical trial or project? Take advantage of our expertise, flexible solutions, and exceptional customer service. Contact us today!